Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 14, 2024

Primary Completion Date

June 21, 2025

Study Completion Date

July 25, 2025

Conditions

Primary Sjögren's Syndrome

Interventions

DRUG

IBI355

IBI355 IV. Q4W

DRUG

IBI355 placebo

IBI355 placebo IV. Q4W

Trial Locations (1)

The First Affiliated Hospital of University of Science and Technology of China, Hefei

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT06484855 - Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome | Biotech Hunter | Biotech Hunter